Clinical Trials

Clinical Trials


Eric Segal, MD

Program description:
The Northeast Regional Epilepsy Group is dedicated to the care of patients with epilepsy and offers a comprehensive program for the diagnosis and treatment of children and adults with epilepsy. The highly experienced epilepsy team includes epileptologists, neurosurgeons, neuropsychologists, nurses and researchers who focus exclusively on epilepsy and seizure disorders. Our expanding research program includes clinical drug trials and other research efforts to better understand the best use of existing treatment options and to test promising new treatments.

Research activities:
Nearly 3 million Americans are affected by epilepsy and approximately 30% of all epilepsies are uncontrolled.  Although 10 new anti-seizure medications have been brought to market over the last decade, the percentage of patients with epilepsy responding to treatment has not changed.  Our investigators continue the effort to find new treatments for epilepsy.  Research studies are both multi-center (national and international) and single-center. By participating in clinical trials, patients may have access to leading-edge treatments and therapies.

Other resources:

For more information about research studies at Northeast Regional Epilepsy Group, please contact:

Director of Research
Eric Segal, MD

Clinical Research Coordinator
Munazza Malik, MD
(201) 343-6676

Open Clinical Studies:

1. An Open - Label Multicenter safety and pharmacokinetic study of YKP3089 as adjunctive therapy in patients with partial onset seizures.

2.  A Double0Blind, Placebo-Controlled, Dose escalation study with an Open-Label phase to examine the Safety, Tolerability, PK and PD of TAK935 as an adjunct Therapy in subjects with developmental or Epileptic Encephalopathies.

3.  Cognitive and behavioral effects of perampanel (Fycompa)  As adjunctive therapy in patients with partial epilepsy.

4.  An Open-Label, Multicenter study with an Extension Phase to Evaluate the Safety , Tolerability, and Exposure-Efficacy Relationship of Perampanel Oral suspension when Administered as an Adjunctive Therapy in pediatric Subjects (Age 4 to less than 12years) with inadequately Controlled Partial-Onset Seizures or Primary generalized Tonic-Clonic seizures

5.  A randomized, double-blind, placebo- controlled study to investigate the safety and efficacy of cannabidiol (GWP42003-P) in children and young adults with Dravet Syndrom.

6.  A Multicenter, Randomized, double-blind, parallel group, placebo- controlled trial of two fixed doses of ZX008 (Fenfluramine hydrochloride) oral solution as an adjunctive therapy in children and young adults with Dravet Syndrome.

7.  An Open Label-Extension trial to assess the long-term safety of ZX008 (Fenfluramine Hydrochloride) oral solution as an Adjunctive Therapy in children and young adults with Dravet Syndrome.

8.  1042-0900: A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy and Other Rare Genetic Epilepsies Followed by 52 Week Open-Label Extension


Make an appointment